Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research

被引：0

作者：

Nicola Silvestris

Gennaro Ciliberto

Paolo De Paoli

Giovanni Apolone

Maria Luisa Lavitrano

Marco A. Pierotti

Giorgio Stanta

机构：

[1] Medical Oncology Unit and Scientific Directorate,

[2] Cancer Institute “Giovanni Paolo II”,undefined

[3] Scientific Directorate,undefined

[4] IRCCS National Cancer Institute “Regina Elena”,undefined

[5] Scientific Directorate,undefined

[6] IRCCS “Centro di Riferimento Oncologico”,undefined

[7] Scientific Directorate,undefined

[8] Fondazione IRCCS Istituto Nazionale dei Tumori,undefined

[9] BBMRI.it and Department of Medicine and Surgery University Milano-Bicocca,undefined

[10] Senior Group Leader Foundation Institute FIRC Molecular Oncology (IFOM) Milan,undefined

[11] Department of Medical Sciences of the University of Trieste,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 36卷

关键词：

Dynamic; Fluid; Personalized medicine; Target therapy; Clinical trials; N-of-1 trials;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term “Liquid dynamic medicine” in the place of “Personalized or Precision medicine”. Clinical validation of the “Liquid dynamic medicine” approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.

引用

共 50 条

[1] Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
Silvestris, Nicola
Ciliberto, Gennaro
De Paoli, Paolo
Apolone, Giovanni
Lavitrano, Maria Luisa
Pierotti, Marco A.
Stanta, Giorgio
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
[2] N-of-1 trials in oncology
Collette, Laurence
Tombal, Bertrand
LANCET ONCOLOGY, 2015, 16 (08): : 885 - 886
[3] N-of-1 Clinical Trials
O'Connor, Christopher M.
JACC-HEART FAILURE, 2019, 7 (07) : 630 - 631
[4] N-of-1 randomized controlled trials ('N-of-1 trials'): singularly useful in geriatric medicine
Price, JD
Evans, JG
AGE AND AGEING, 2002, 31 (04) : 227 - 232
[5] N-of-1 trials: The epitome of personalized medicine?
Samuel, Joyce P. P.
Wootton, Susan H. H.
Tyson, Jon E. E.
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
[6] N-of-1 Precision Medicine and Research Oversight
Crouse, Andrew
Nakano-Okuno, Mariko
Might, Matthew
May, Thomas
AMERICAN JOURNAL OF BIOETHICS, 2019, 19 (08): : 36 - 37
[7] Application of n-of-1 Clinical Trials in Personalized Nutrition Research: A Trial Protocol for Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR)
Tian, Yunyi
Ma, Yue
Fu, Yuanqing
Zheng, Ju-Sheng
CURRENT DEVELOPMENTS IN NUTRITION, 2020, 4 (09):
[8] N-of-1 medicine
Wang, Peter
Leong, Qiao Ying
Lau, Ni Yin
Ng, Wei Ying
Kwek, Siong Peng
Tan, Lester
Song, Shang-Wei
You, Kui
Chong, Li Ming
Zhuang, Isaiah
Ong, Yoong Hun
Foo, Nigel
Tadeo, Xavier
Kumar, Kirthika
Vijayakumar, Smrithi
Sapanel, Yoann
Raczkowska, Marlena Natalia
Remus, Alexandria
Blasiak, Agata
Ho, Dean
SINGAPORE MEDICAL JOURNAL, 2024, 65 (03) : 167 - 175
[9] Methodological Considerations in N-of-1 Trials of Traditional Chinese Medicine
Huang, Haiyin
An, Jiaqi
Lu, Lizhi
Wang, Mingli
Chen, Huijia
Chen, Xinlin
Shen, Lihua
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
[10] N-of-1 clinical trials should be incorporated into clinical practice
Berlin, Jesse A.
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (12) : 1283 - 1284

← 1 2 3 4 5 →